Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161821 · ClinicalTrials.gov registry record
Circulating Tumor Cells in Solid Tumors
A clinical trial, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- 206
- Enrollment target
NCT03161821: Completed study, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT03161821 is a clinical trial that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03161821 has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer. Develop a database and a sample repository where future analysis could be done.
Primary Outcome
Enumeration of participants' circulating solid tumor cells
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2011-12-09 |
| Est. Completion | 2021-02-16 |
What the finished NCT03161821 record still lists
NCT03161821 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT03161821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03161821 about?
NCT03161821 is a clinical study titled "Circulating Tumor Cells in Solid Tumors". The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer. Develop a database and a sample repository where future analysis could be done.
What is the current status of trial NCT03161821?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2011-12-09. Estimated completion is 2021-02-16.
What interventions are being tested in trial NCT03161821?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT03161821?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI